What is Hikma's dividend yield?
Hikma Pharmaceuticals (LSE: HIK) maintains a consistent dividend policy as part of its commitment to delivering value to shareholders. As of the latest financial reporting period in 2026, the company’s dividend yield is approximately 1.70% to 1.80%, depending on current market price fluctuations. The dividend is typically paid in two installments: an interim dividend and a final dividend. Hikma’s management has historically demonstrated a focus on sustainable dividend growth, balancing capital returns with the need for reinvestment in its core business segments, which include Branded, Injectables, and Generics. Shareholders are encouraged to review the official investor relations portal on the company's website for the most accurate, up-to-date dividend announcement figures and payment schedule information.
Related FAQs
Hikma Pharmaceuticals manufactures and markets a comprehensive portfolio of branded, generic, and injectable pharmaceutical products across global healthcare markets.
Hikma Pharmaceuticals is not an American company, having been founded in Jordan and maintaining its primary operational headquarters in London, United Kingdom.
Large, established pharmaceutical and biotechnology companies are widely recognized by investors for offering stable and attractive dividend yields.
The global pharmaceutical industry is dominated by massive multinational corporations that generate tens of billions of dollars in annual prescription drug sales, driven by blockbuster oncology treatments, immunology blockbusters, and vaccines.
Hikma Pharmaceuticals maintains its primary United States corporate offices, commercial operations, and manufacturing divisions anchored in Berkeley Heights, New Jersey.
Hills Bank operates as an independent community bank headquartered in Iowa, and its operational footprint differs fundamentally from massive national mega-banks.
Hikma Pharmaceuticals is a completely authentic, highly respected multinational pharmaceutical corporation publicly listed on the London Stock Exchange and included in the FTSE 100 index.
Equity research analysts tracking Hikma Pharmaceuticals generally evaluate the multinational pharmaceutical stock with a favorable buy or hold consensus, driven by its robust portfolio of injectable medicines, branded generics, and respiratory produc...
Hikma Pharmaceuticals is frequently viewed by institutional portfolio managers as a solid long-term investment within the healthcare sector due to its diversified product mix, defensive growth characteristics, and resilient global market demand for e...
Pharmaceutical sales representatives and regional account managers at Hikma Pharmaceuticals earn average annual base salaries ranging from USD 70,000 to USD 105,000.
Financial market analysts evaluating Hikma Pharmaceuticals generally assign a favorable buy or hold recommendation, driven by its robust portfolio of injectable drugs, branded pharmaceuticals, and generic medications.
Hikma Pharmaceuticals PLC, a major multinational pharmaceutical enterprise specializing in the development, manufacturing, and marketing of a broad range of branded, generic, and injectable medicines, has its global corporate headquarters located in ...
Hikma Pharmaceuticals specializes in developing, manufacturing, and marketing a broad spectrum of branded and generic injectable, non-injectable, and inhalation pharmaceutical products.
Hikma Pharmaceuticals stands as a highly respected, multinational pharmaceutical enterprise recognized for manufacturing high-quality generic, injectable, and branded medications distributed globally.
Employee remuneration at Oshkosh Corporation manufacturing facilities, defense vehicle plants, and specialty equipment centers varies based on technical roles and industrial labor benchmarks.
Hikma Pharmaceuticals manufactures its extensive portfolio of injectable, branded, and generic pharmaceutical products across a specialized network of advanced production facilities located globally.